Full Press Release Details
Medical Appoints the Co-Founder of Corindus Vascular Robotics to its Board of Directors
Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic System
Mass., August 3, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) has further strengthened the Company's capabilities
and expertise as Mr. Tal Wenderow, an experienced medical device and robotics executive with a proven track record in small and
mid-size companies, has been appointed to the Company's Board of Directors. Mr. Wenderow co-founded Corindus Vascular Robotics,
a robotic-assisted vascular interventions company, and contributed to the company's success, leading to its$1.1 billion
acquisition by Siemens Healthineers AG in October 2019.
and aligned with our strategic objectives, one of which is enhancing our core leadership capabilities, Tal's leadership
and proven track record will contribute greatly to the future success of Microbot," commented Harel Gadot, CEO, President
and Chairman. "His contributions to Corindus' growth, from inception through the recently completed acquisition by
Siemens Healthineers AG, are well chronicled. I welcome him to the Board and look forward to his many contributions as we progress
our multi-generation product portfolio, and especially the LIBERTY Robotic system given his extensive knowledge in the vascular
interventional market."
over 19 years of industry experience, Mr. Wenderow holds multiple patents and is a recognized thought leader in the vascular interventions
market. He is currently the President and CEO of Vocalis Health, a global technology leader in vocal biomarkers developing voice-enabled
AI solutions to create proprietary vocal biomarkers for personalized healthcare screening and continuous remote monitoring of
health by using a simple voice sample. At Corindus, Mr. Wenderow served several executive leadership roles, including Chief Executive
Officer and Executive Vice President of International & Business Development, and demonstrated strong business execution to
achieve the company's strategic objectives. Mr. Wenderow holds a B.Sc. summa cum laude in Mechanical Engineering from Technion
in Israel and has completed the Executive Program for Life Sciences at the Merage Foundation, Merage Business School, University
of California, Irvine, CA.
am extremely excited to join the Microbot Board of Directors and support the next revolution of the healthcare robotic space,"
commented Mr. Wenderow. "Microbot is developing a portfolio of innovative medical robotic devices that have the potential
to address sizeable market opportunities. The depth of the entire team is very impressive including Professor Moshe Shoham, who
is a known leader and innovator in the robotic market. I look forward to collaborating and working with each of them to achieve
Microbot's objectives."
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at http://www.microbotmedical.com.
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome
of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical
can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities
and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the
SEC, which are or will be available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by law.